Harrow Inc

Harrows insider buy and new CSO appointment signal confidence in eye‑care pipeline; investors eye potential upside amid modest transaction size.

Insider buying at Harrow Inc. signals confidence amid market volatility, showing senior leaders trust the ophthalmic pipeline and future regulatory approvals.

CEO Mark Baum’s fresh $30.20 buy of 10 k shares shows confidence amid a 20 % drop, hinting at a potential rebound for Harrow as revenue stays strong.

Opaleye’s sharp insider sell‑off of 140k Harrow shares amid a bearish market may signal short‑term pain, but the company’s upcoming trial results could tilt the narrative toward growth. Explore the details.

Opaleye Management’s recent Harrow sell signals a tactical pullback amid market volatility—insider moves hint at cautious profit‑taking, not a loss of faith.